Market Report Source

Overview

Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth.

The Indian Pharmaceutical Market to 2011 provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. For each company, this report analyzes current and future therapeutic focus, sales growth, key pipeline products and future growth prospects. This report will help you to identify the critical success factors that have driven company growth, evaluate diversification opportunities and assess the future potential of each company’s R&D portfolio over the next five years.

Table of Contents

The Indian pharmaceutical market to 2011
Executive Summary
The Indian Pharmaceutical Market
Company Analysis
Future Outlook for the Indian pharmaceutical industry
Chapter 1 The Pharmaceutical Market Environment in India
Summary
Introduction
Pharmaceutical market environment in India
Pharmaceutical spending in the Indian market
Performance of Therapeutic Areas
Performance of leading companies in the Indian market
Leading products in the Indian pharmaceutical market
Factors shaping the Indian pharmaceutical market
Chapter 2 Company analysis
Summary
Introduction
Indian Market analysis by company
Cipla
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D Pipeline
Strategic Positioning
SWOT analysis
Corporate Strategy
Ranbaxy
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D Pipeline
Strategic Positioning
SWOT analysis
Corporate Strategy
Nicholas Piramal
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D Pipeline
Strategic Positioning
SWOT analysis
Corporate Strategy
Sun Pharmaceuticals
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D Pipeline
Strategic Positioning
SWOT analysis
Corporate Strategy
Zydus Cadila
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D Pipeline
Strategic Positioning
SWOT analysis
Corporate Strategy
Dr. Reddy’s
Overview
Geographic analysis
Product portfolio analysis
Sales focus by therapy area
Marketed portfolio
R&D pipeline
Strategic positioning
SWOT analysis
Corporate strategy
Alkem
Company Overview
Geographic Presence
Product Portfolio Analysis
Sales focus by therapy area
Marketed Portfolio
R&D pipeline
Strategic Positioning
SWOT analysis
Corporate strategy
Lupin
Company overview
Geographic analysis
Product portfolio
Sales focus by therapy area
Marketed portfolio analysis
R&D pipeline
Strategic positioning
SWOT analysis
Corporate strategy
Aristo
Company overview
Geographic analysis
Product portfolio
Sales focus by therapy area
Marketed portfolio analysis
R&D pipeline
Strategic Positioning
SWOT analysis
Corporate strategy
Torrent
Company overview
Geographic analysis
Product portfolio
Sales focus by therapy area
Marketed portfolio analysis
R&D pipeline
Strategic Positioning
SWOT analysis
Corporate strategy
Company forecast sales for the period 2005-11.
Chapter 3 Future Outlook and Competitive Pressures
Summary
Introduction
Competitive pressures being faced by the Indian companies
Re-introduction of product patent regime in 2005
Market saturation in the Indian market across major therapy areas
Increasing competition from other low cost manufacturing markets such as
China
Stringent pricing controls on numerous essential medicines
Future Indian pharmaceutical growth models
Value versus volume driven market
Contract Research and Manufacturing Sourcing (CRAMS)
Contract Manufacturing
Contract Research and low cost clinical trials
Mergers and acquisitions
Chapter 4 Appendix
IMS data
Index
List of Figures
Figure 1.1: Comparison of pharmaceutical sales in the markets of India, EU5, US, Brazil, Russia,
China and Japan, 2005
Figure 1.2: Comparison of pharmaceutical spending in the markets of India, EU5, and the US,
2005
Figure 1.3: Sales performance of different therapeutic areas in the Indian market, 2005
Figure 1.4: Competitive Dynamics between the 20 leading companies in India, 2005
Figure 1.5: Competitive dynamics between leading brands in the Indian market, 2005
Figure 1.6: Factors shaping the Indian pharmaceutical market
Figure 2.7: Share of Indian companies by sales, 2005
Figure 2.8: Cipla’s geographic presence, 2005
Figure 2.9: Cipla therapeutic areas sales performance, 2004-5
Figure 2.10: Cipla’s SWOT Analysis
Figure 2.11: Cipla’s future direction
Figure 2.12: Ranbaxy geographic presence, 2005
Figure 2.13: Ranbaxy therapeutic areas sales performance, 2004-05
Figure 2.14: Ranbaxy’s SWOT Analysis
Figure 2.15: Ranbaxy future direction
Figure 2.16: NPIL’s therapeutic areas sales performance, 2001-05
Figure 2.17: NPIL’s SWOT Analysis
Figure 2.18: Nicholas Piramal’s future direction
Figure 2.19: Sun Pharmaceutical’s geographic presence, 2005
Figure 2.20: Sun Pharma’s therapeutic areas sales performance, 2004-05
Figure 2.21: Sun Pharma’s SWOT Analysis
Figure 2.22: Sun Pharma’s future direction
Figure 2.23: Zydus Cadila’s geographic presence, 2005
Figure 2.24: Zydus Cadila’s therapeutic areas sales performance, 2004-05
Figure 2.25: Zydus: SWOT Analysis
Figure 2.26: Zydus Cadila’s future direction
Figure 2.27: Dr. Reddy’s geographic presence, 2005
Figure 2.28: Competitive dynamics of Dr. Reddy’s key therapy areas, 2005
Figure 2.29: Dr. Reddy’s SWOT analysis
Figure 2.30: Dr. Reddy’s future direction
Figure 2.31: Alkem’s geographic presence, 2005
Figure 2.32: Alkem’s performance by therapeutic area, 2001-05
Figure 2.33: Alkem’s SWOT analysis
Figure 2.34: Alkem’s future direction
Figure 2.35: Lupin’s geographic presence, 2005
Figure 2.36: Competitive dynamics of Lupin’s key therapy areas, 2005
Figure 2.37: Lupin’s SWOT analysis
Figure 2.38: Lupin’s future direction
Figure 2.39: Competitive dynamics of Aristo’s key therapy areas, 2005
Figure 2.40: Aristo’s SWOT analysis
Figure 2.41: Torrent’s geographic presence, 2005
Figure 2.42: Competitive dynamics of Torrent’s key therapy areas, 2005
Figure 2.43: Torrent’s SWOT analysis
Figure 2.44: Torrent’s future direction
Figure 3.45: Forecast future trends of Indian pharmaceutical companies
Figure 3.46: Future growth opportunities for Indian pharmaceutical companies
List of Tables
Table 1.1: Breakdown of the Indian pharmaceutical market by therapy area, 2001-05
Table 1.2: Sales of leading pharmaceutical companies in India, 2004-05
Table 1.3: Leading brands in the Indian market, 2004–05
Table 2.4: Sales of leading Indian pharmaceutical companies, 2004-05
Table 2.5: Breakdown of the Cipla’s revenues by therapy area, 2001-05
Table 2.6: Leading brands in Cipla’s marketed portfolio, 2004–05
Table 2.7: Cipla’s Commercial Agreements 2001-2007
Table 2.8: Breakdown of the Ranbaxy’s revenues by therapy area, 2001-05
Table 2.9: Leading brands in Ranbaxy’s marketed portfolio, 2004–05
Table 2.10: Ranbaxy’s R&D product pipeline, 2006
Table 2.11: Ranbaxy’s Commercial Agreements 2001-2007
Table 2.12: Breakdown of the Nicholas Piramal’s revenues by therapy area, 2001-05
Table 2.13: Leading brands in NPIL’s marketed portfolio, 2004–05
Table 2.14: NPIL’s R&D product pipeline, 2006
Table 2.15: NPIL’s Commercial Agreements 2001-2007
Table 2.16: Breakdown of the Sun Pharma’s revenues by therapy area,
Table 2.17: Leading brands in Sun Pharma’s marketed portfolio, 2004–05
Table 2.18: Sun Pharma’s R&D product pipeline, 2006
Table 2.19: Sun Pharma’s Commercial Agreements 2001-2007
Table 2.20: Breakdown of Zydus Cadila’s revenues by therapy area, 2001-05
Table 2.21: Leading brands in Zydus Cadila’s marketed portfolio, 2004–05
Table 2.22: Zydus Cadila’s R&D product pipeline, 2006
Table 2.23: Zydus Cadila’s Commercial Agreements 2001-2007
Table 2.24: Breakdown of Dr. Reddy’s revenues by therapy area, 2001-05
Table 2.25: Leading brands in Dr. Reddy’s marketed portfolio, 2004–05
Table 2.26: Dr. Reddy’s R&D product pipeline, 2006
Table 2.27: Dr. Reddy’s corporate agreements 2001-2006
Table 2.28: Breakdown of Alkem’s revenues by therapy area, 2001-05
Table 2.29: Leading brands in Alkem’s marketed portfolio, 2004–05
Table 2.30: Alkem’s corporate agreements 2001-2006
Table 2.31: Breakdown of Lupin’s revenues by therapy area, 2001-05
Table 2.32: Leading brands in Lupin’s marketed portfolio, 2004–05
Table 2.33: Lupin’s R&D product pipeline, 2006
Table 2.34: Lupin’s corporate agreements 2001-2006
Table 2.35: Breakdown of Aristo’s revenues by therapy area, 2001-05
Table 2.36: Leading brands in Aristo’s marketed portfolio, 2004–05
Table 2.37: Breakdown of Torrent’s revenues by therapy area, 2001-05
Table 2.38: Leading brands in Torrent’s marketed portfolio, 2004–05
Table 2.39: Torrent’s R&D product pipeline, 2006
Table 2.40: Torrent’s corporate agreements 2001-2006
Table 2.41: Company sales forecasts for the Indian market, 2005-11